Vendor Intelligence Report: GrayPep

Published 2 Jul 2026. 17-page investigative report on who is behind GrayPep: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 3 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 4 Finnrick lab tests, GrayPep records 4 pass / 0 fail, an overall pass rate of 100%. That clean headline is also narrow: every tested sample is Tirzepatide. For a buyer choosing GrayPep specifically for Tirzepatide, the evidence is materially stronger than for the rest of the catalogue; Retatrutide, BPC-157, Tesamorelin and NAD+ remain outside GrayPep’s Finnrick-tested footprint. The full report also stress-tests the Tirzepatide record under stricter Finnrick scoring.

The investigation found a vendor with a real product signal but a lightly anchored operating identity. Graypep.com presents Hgp biotech branding, HGP-style handles and first-name contacts through Gmail, Telegram and WhatsApp, while the captured materials do not identify a registered legal seller, company officer, physical address or manufacturing address. That is an accountability finding, not a fraud finding.

The documents behind the marketing claims are the main gap. GrayPep claims long experience, GMP-certified manufacturing, broad purity standards and batch testing, but the public pages captured in this run did not provide a certificate, facility record, sample COA portal or named partners. The Wayback Machine showed no snapshots for graypep.com, the tested Privacy Policy and Terms & Conditions URLs returned 404, and a Trustpilot lead for hgppeptides.com pointed to a non-resolving domain. The report also separates broader CBP peptide-seizure context from any direct attribution to GrayPep.

Inside the full report:

  • Complete Tirzepatide pass/fail record, rating trajectory and methodology-divergence charts.
  • Homepage and About Us exhibits showing GrayPep/Hgp biotech branding, Jay and Richard contact routes, and marketing claims.
  • Corporate-accountability absence trail covering entity checks, registry/tooling limitations and missing legal pages.
  • Branding and domain analysis of HGP handles, hgppeptides.com, Trustpilot residue and official-channel verification gaps.
  • Supply-chain and shipping-risk analysis using the CBP Cincinnati seizure release with explicit attribution boundaries.
  • Reputation and promotion sweep covering Reddit, X/web affiliate scans, coupon searches and private-channel limitations.

Risk assessment

  • Corporate-accountability risk — high: No verifiable legal entity or physical address was identified; public contacts are first-name operators using Gmail/WhatsApp/Telegram across China/UK.
  • Brand-authenticity and domain-confusion risk — medium: graypep.com presents as Hgp biotech, a Trustpilot page exists for non-resolving hgppeptides.com, and no official-channel/reseller/anti-counterfeit verification system is published.
  • Unverified history and GMP-credential claims — medium: Website claims 7+ years, GMP-certified manufacturing and 99%+ purity, but no Wayback history, certificate, facility address, sample COA, or named partners were found.
  • Product-specific quality evidence gap outside Tirzepatide — medium: Tirzepatide is 4/4 pass with an 82.91% Finnrick rating; listed alternatives such as Retatrutide, Tesamorelin, NAD+, BPC-157 and CJC-1295 NO DAC have no Finnrick record.
  • Customs/seizure and shipping-continuity risk — medium: Vendor advertises reshipment if seized; CBP documented Dec 2025–Mar 2026 China-origin peptide seizures including Tirzepatide/Retatrutide, with no direct GrayPep link established.
  • Buyer-recourse and policy-documentation risk — medium: Privacy Policy and Terms & Conditions URLs returned 404, leaving no accessible refund, liability, privacy, or dispute terms in the materials.